Entries |
Document | Title | Date |
20080200549 | PHARMACEUTICAL COMPOSITION OF IBUPROFEN AND PARACETAMOL AND METHODS OF USING THE SAME - A combination pharmaceutical composition for the treatment of pain comprising between about 125 mg and about 150 mg ibuprofen and between about 475 mg and about 500 mg paracetamol, and a method for alleviating pain in a patient comprising administering to the patient a pharmaceutical composition comprising between about 125 mg and about 150 mg ibuprofen and between about 475 mg and about 500 mg paracetamol. | 08-21-2008 |
20080214669 | Composition and Method For Treating Hyperpigmented Skin - An improved cosmetic and dermatological composition and a method for treating hyperpigmented skin is disclosed. The composition demonstrates an enhanced ability to lighten mammalian skin color, and is nontoxic and nonirritating. The composition comprises a hydroxycinnamic acid or a methoxycinnamic acid dissolved in a compound having one or more hydroxy groups, like a monoC | 09-04-2008 |
20080269334 | Highly Concentrated Pourable Aqueous Solutions Of Potassium Ibuprofen, Their Preparation And Their Use - Concentrated pourable potassium ibuprofen liquid compositions, and preparation and uses thereof are described. They are composed of (i) at least 60 wt % of potassium ibuprofen in dissolved form; (ii) water; (iii) one or more polyethylene glycols, (iv) optionally up to 5 wt % of at least one C | 10-30-2008 |
20080280985 | Methods and Compositions Using Certain Phenolic Derivatives for the Treatment of Diabetes - This present invention provides methods and pharmaceutical compositions for the treatment or prophylaxis of diabetes and related disorders, comprising the administration of an effective amount of a compound including an optionally substituted phenyl ring linked to an aromatic or alkyl group by a spacer, wherein the spacer includes two groups selected from selenium, sulfur, S(O) and S(O) | 11-13-2008 |
20080312327 | Organic Compositions - Provided is an improved liquid composition for the treatment of surfaces, preferably the skin and/or hair in order to provide a cleaning and/or sanitizing effect thereto, which necessarily comprises: one or more detersive surfactants selected from anionic, nonionic, cationic, and amphoteric surfactants; a first biocidal constituent(s) which provide a biocidal effect in conjunction with at least one or more second biocidal constituent(s) selected from benzoic acid, benzoic acid derivatives and salts thereof or farnesol, one or more pH adjusting constituents, optionally one or more organic solvents, hydrotropes, and further additive constituents, and water. In preferred embodiments the hydrotrope and/or organic solvents are desirably excluded from the compositions, and the composition is thickened. The compositions are particularly useful as a hand wash composition, body wash or shampoo. | 12-18-2008 |
20090012173 | Method for treatment of nocturia - A method for treatment of nocturia by administering to a mammal, such as a human, in need of such treatment, a therapeutically effective amount of loxoprofen or a pharmacologically acceptable salt thereof. | 01-08-2009 |
20090048345 | IMMEDIATE RELEASE AND SUSTAINED RELEASE IBUPROFEN DOSING REGIMEN - A method of administering non-steroidal-anti-inflammatory drugs, in particular propionic acid derivatives such as ibuprofen, is provided. The inventive dosage forms provide an initial release of the NSAID and a second sustained release of NSAID, preferably in a single dosing step. | 02-19-2009 |
20090062394 | TRANSDERMAL DELIVERY OF KETOPROFEN POLAR DERIVATIVES - A topical or transdermal composition including a polar derivative of ketoprofen and a pharmaceutically acceptable topical or transdermal carrier, wherein the polar derivative of ketoprofen comprises a polarity that is greater than that of ketoprofen. | 03-05-2009 |
20090105344 | BIPHENYL CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | 04-23-2009 |
20090105345 | AMIDE LINKED MODULATORS OF Gamma-SECRETASE - The present invention relates to compounds of Formula I as shown below, wherein the definitions of A, R | 04-23-2009 |
20090118372 | Inhibitors Of Biotin Protein Ligase - The present invention relates to a method for identifying an inhibitor of a biotin protein ligase. The method include the steps of (a) providing a substrate, wherein the substrate may be biotinylated; (b) contacting the substrate with biotin and a biotin protein ligase in the presence of a test compound; (c) determining the extent of biotinylation of the substrate by the biotin protein ligase in the presence of the test compound; and (d) identifying the test compound as an inhibitor of the biotin protein ligase by a reduction in the biotinylation of the substrate in the presence of the test compound as compared to the extent of biotinylation of the substrate in the absence of the test compound. | 05-07-2009 |
20090156681 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS - Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. | 06-18-2009 |
20090170949 | Method To Control Body Weight - The present invention relates to a method to treat obesity and/or a method to lose or control body weight. More specifically, the invention relates to the use of a compound inhibiting the sweet taste perception, preferably by inactivating the T1R3 receptor, for the preparation of a medicament to treat or prevent obesity and/or to treat or prevent diabetes and/or to lose or control body weight. | 07-02-2009 |
20090176883 | TRPA1 Antagonists - Compounds of formula (I) | 07-09-2009 |
20090176884 | PHARMACEUTICAL SUSPENSION COMPOSITION - An aqueous oral liquid pharmaceutical composition system with reduced propensity for agglomeration and phase separation which is particularly amendable to the suspension of one or more pharmaceutical actives that are substantially insoluble in water. The oral liquid pharmaceutical composition may further comprise pharmaceutical actives that are soluble in water and dissolve in the aqueous medium. In the composition of the invention both suspended and any dissolved active agents are distributed homogeneously. | 07-09-2009 |
20090203793 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS - Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyper-lipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed as Formula (I). | 08-13-2009 |
20090209649 | ALPHA-GLUCOSIDASE INHIBITOR, INHIBITOR FOR BLOOD GLUCOSE LEVEL ELEVATION AND FUNCTIONAL FOOD CONTAINING TRICAFFEOYLALDARIC ACID AND METHOD FOR PRODUCING TRICAFFEOYLALDARIC ACID - Components that demonstrate an α-glucosidase inhibitory activity and hyperglycemic inhibitory activity have clearly been provided from among the components included in Yacon. The present inventors found that as a result of screening for a strong anti-oxidant component in a Yacon aerial portion extract, an antioxidant activity was converged in a DIAION HP-20 column chromatography 50% methanol-eluted fraction of hot water extract. Thus, since a previously unidentified high-content component was confirmed, the present inventors conducted purification thereof, and thereby separated TCAA. As a result, this TCAA was found to be the component that demonstrates the α-glucosidase inhibitory activity and hyperglycemic inhibitory activity. | 08-20-2009 |
20090215901 | Methods for treatment of nocturia - A method for the treatment of nocturia which consists of administering to a mammal in need of such treatment a therapeutically effective amount of a nonsteroidal anti-inflammatory drug consisting of loxoprofen or a pharmacologically acceptable salt thereof, wherein the mammal is a human who has a neurogenic bladder. | 08-27-2009 |
20090234013 | PHARMACEUTICAL COMPOSITIONS HAVING DESIRABLE BIOAVAILABILITY - The present invention is directed to the provision of pharmaceutical compositions. The compositions include a therapeutic agent and a relatively low amount of surfactant for providing higher bioavailability of the therapeutic agent. The compositions are particularly desirable as ophthalmic compositions in which the therapeutic agent is a prostaglandin such as travoprost and the surfactant is a vegetable oil such as castor oil. | 09-17-2009 |
20090281190 | NOVEL ATTRACT AND KILL COMPOSITION FOR CONTROL OF PEST INSECTS - The invention relates to a composition and procedure to attract and kill insect pests. An insecticidal attract-and-kill composition comprising: an organic biodegradable matrix component from natural sources; an organic biodegradable ultraviolet light absorbent matrix component from natural sources; a biodegradable insecticidal or acaricidal compound; and a pheromonal or kairomonal attractant. | 11-12-2009 |
20090286882 | Cyclopropylacetic Acid Derivatives and Use Thereof - The present application relates to novel cyclopropylacetic acid derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prevention of cardiovascular disorders. | 11-19-2009 |
20090312426 | PROCESS OF PREPARING DERIVATIVES OF 1-(2-HALOBIPHENYL-4-YL)-CYCLOPROPANECARBOXYLIC ACID - Compounds represented by formula (I): | 12-17-2009 |
20100041758 | ADHESIVE PREPARATION - An adhesive preparation which has a pressure-sensitive adhesive layer comprising two components, i.e., a C1-4 alcohol ester of 4-{[2-((1R,2R,3R)-3-hydroxy-2-{(1E,3S)-3-hydroxy-4-[3-(methoxymethyl)phenyl]but-1-enyl}-5-osocyclopentyl)ethyl]sulfanyl}butanoic acid and a silicone-based pressure-sensitive adhesive. This is an effective and safe preparation which is stable, shows little change in skin permability and release a drug not rapidly but continuously. | 02-18-2010 |
20100048710 | Methods and Compositions for Modulating Muscle Fat in Livestock - The present invention relates to compositions and methods for modulating the degree of adipose tissue deposited intramuscularly in livestock animals. In particular, the present invention relates to compositions and methods for the use of non-steroidal antiinflammatory drugs to preferentially increase the amount of intramuscular adipose tissue in cattle. | 02-25-2010 |
20100069496 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS - The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR delta modulators to treat or inhibit the progression of, for example, dyslipidemia. | 03-18-2010 |
20100099768 | 1-PHENYLALKANECARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES - 1-Phenylalkanecarboxylic acid derivatives, the processes for the preparation thereof and the use thereof in the treatment and/or prevention of neurodegenerative diseases such as Alzheimer's disease. | 04-22-2010 |
20100105775 | AMINO ACID SALTS OF PROSTAGLANDINS - The present invention is directed to novel amino acid prostaglandin salts and methods of making and using them. | 04-29-2010 |
20100137443 | Ibuprofen for Topical Administration - Set forth herein is a preparation of ibuprofen (2-(4-isobutylphenyl)propionic acid) in the free acid form that is suitable for topical administration. The topical ibuprofen formulation is prepared by dissolving the free acid form of ibuprofen, or preparing a homogeneous suspension of the free acid form of ibuprofen, in the presence of a pharmaceutically acceptable solvent so as to produce a topical drug formulation compatible with the penetration of 2-(4-isobutylphenyl) propionic acid through the skin tissue. Topical formulations of ibuprofen can be based on a pharmaceutically acceptable solvent such as, e.g., a pyrrolidone solvent or dimethylacetamide. | 06-03-2010 |
20100144884 | NOVEL 3-PHENYL ACRYLIC ACID COMPOUND ACTIVATORS OF TYPE PPAR RECEPTORS AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF - Novel 3-phenyl acrylic acid compounds have the following general formula (I): | 06-10-2010 |
20100184861 | METHOD AND APPARATUS FOR DRY GRANULATION - The invention provides, inter alia, a method for producing granules from a powder, characterized in that compaction force is applied to the powder to produce a compacted mass comprising a mixture of fine particles and granules and separating and removing fine particles and/or small granules from the other granules by entraining the fine particles and/or small granules in a gas stream. Also provided are apparatus for use in the process and tablets formed by compression of the resultant granules. | 07-22-2010 |
20100234463 | Method for Identifying Modulators of Gamma Secretase or Notch - The present invention relates to methods for high throughput screening to identify selective modulators of γ-secretase. Such modulators selectively block γ-secretase activity without affecting Notch cleavage and signaling. Said methods employ the use of high content screening methodologies to measure and quantify the translocation of the Notch intracellular domain (NICD) between the nucleus and cytoplasm in cells and the activation of Notch. | 09-16-2010 |
20100234464 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS - 3-(2,4-Bis(trifluoromethyl)benzyloxy)phenylacetic acid, 4-(2,6-Dimethylbenzyloxy)-phenylacetic acid, and their pharmaceutically acceptable salts are useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis. | 09-16-2010 |
20100234465 | Administration of Intravenous Ibuprofen - An effective dose of intravenous ibuprofen administered every 6 hours in surgery patients is a safe and effective way to reduce both pain and the need for morphine. In preferred embodiments, the administration of intravenous ibuprofen starts with the onset of anesthesia. | 09-16-2010 |
20100240758 | EXTERNAL PREPARATION FOR PERCUTANEOUS ADMINISTRATION CONTAINING NONSTEROIDAL ANTI-INFLAMMATORY ANALGESIC - An external preparation for percutaneous administration which contains a light-sensitive nonsteroidal anti-inflammatory analgesic and a UVA-shielding agent which inhibits the analgesic to cause light toxicity and a light allergy. This external preparation for percutaneous administration, which contains a nonsteroidal anti-inflammatory analgesic, can be prevented, with higher certainty, from causing the hypersensitivity to light attributable to light toxicity and a light allergy. | 09-23-2010 |
20100249234 | METHODS OF REDUCING VIRULENCE IN BACTERIA - A method of reducing virulence in a bacterium comprising at least one of a GacS/GacA-type system, a HrpX/HrpY-type system, a T3SS-type system, and a Rsm-type system, the method comprising contacting the bacterium with an effective amount of a phenylpropanoid-type inhibitory compound. | 09-30-2010 |
20100249235 | ADMINISTRATION OF 3,5-DIIODOTHYROPROPIONIC ACID FOR STIMULATING WEIGHT LOSS, AND/OR LOWERING TRIGLYCERIDE LEVELS, AND/OR TREATMENT OF METABOLIC SYNDROME - The invention provides methods and compositions for stimulating weight loss or lowering triglyceride levels in an individual in need thereof. In methods of the invention, a pharmaceutical composition comprising a therapeutically effective amount of DITPA, and optionally one or a plurality of lipid lowering agents, is administered to an individual to stimulate weight loss, lower triglyceride and/or lipoprotein levels, and/or to treat one or more symptoms of metabolic syndrome. | 09-30-2010 |
20100249236 | ADHESIVE AND PLASTER - An adhesive comprising a base with tackiness, an oil and ketoprofen, wherein the adhesive contains no L-menthol, the base is composed at least of a tacky composition comprising an elastomer and a tackifier and/or a tacky polymer containing an unsaturated monomer with a total of 5 or more carbon atoms as the monomer unit, the oil is an oil that is compatible with the tacky composition and the tacky polymer, and the oil content is 150-175 parts by weight with respect to 100 parts by weight as the total of the tacky composition and the tacky polymer. | 09-30-2010 |
20100249237 | Non-Steroidal Anti-Inflammatory Drug Dosing Regimen - A method of administering non-steroidal-anti-inflammatory drugs, in particular propionic acid derivatives such as ibuprofen, or acetaminophen is provided. This method provides improved therapeutic effect, in particular pain relief, over extended time periods. | 09-30-2010 |
20100280122 | TRANSDERMAL DELIVERY OF BENEFICIAL SUBSTANCES EFFECTED BY A HOSTILE BIOPHYSICAL ENVIRONMENT - The present invention generally relates to the transdermal delivery of substances and, in some embodiments, to the transdermal delivery of beneficial substances by a hostile biophysical environment. In one aspect, various methods for the transdermal delivery of beneficial substances are disclosed. By creating a hostile biophysical environment, beneficial substances may be delivered, according to certain embodiments, through the stratum corneum of the skin into the body. Beneficial substances include, but are not limited to, pharmaceutical agents, drugs, vitamins, co-factors, peptides, dietary supplements, and others. The beneficial effects disclosed include, for instance, relief of pain and inflammation, prevention and healing of ulcers of the skin, relief of headache, improved sexual function and enjoyment, growth of hair on the scalp, improving muscle size and/or function, removing body fat and/or cellulite, treating cancer, treating viral infections and others. A hostile biophysical environment may also be used in conjunction with systems and methods for increasing local blood flow, according to one set of embodiments. For example, by using a nitric oxide donor such as L-arginine, local blood flow may be increased, e.g., by transdermally delivering the nitric oxide precursor. The nitric oxide donor may be the sole cause of increased blood flow, or it may be supplemented with an adjunct such as theophylline. | 11-04-2010 |
20100286278 | Composition comprising an HDAC inhibitor in combination with a retinoid - The present invention is directed to compositions which contain a combination of at least one histone deacetylase inhibitor (HDAC inhibitor) and a retinoid. The composition is in particular a cosmetic preparation. It was found that the combination of an HDAC inhibitor and retinol or a derivative thereof is in particular useful for treating wrinkles but also for thickening the epidermis and for improving hair growth. | 11-11-2010 |
20100311839 | Burst Drug Release Compositions - A solid dose composition comprising at least one pharmaceutically active ingredient and at least one controlled release agent and method of manufacturing said composition is disclosed. The burst profile of at least one pharmaceutically active ingredient in the composition is regulated by the apparent viscosity of the controlled release agent and wherein at least one pharmaceutically active ingredient is processed by wet granulation. | 12-09-2010 |
20110003895 | Pharmacology of Visual Cycle Modulators - Described herein are methods for the treatment of an ophthalmic disease or disorder comprising the administration of non-retinoid visual cycle modulators. | 01-06-2011 |
20110028556 | TREATING CRITICALLY ILL PATIENTS WITH INTRAVENOUS IBUPROFEN - Methods of treating at least one condition chosen from pain, inflammation, and fever in a critically ill patient in need thereof, comprising administering to the critically ill patient an intravenous pharmaceutical composition comprising ibuprofen using a first dosage regimen, wherein the first dosage regimen produces a first pharmacokinetic profile in critically ill patients that is about equivalent to a second pharmacokinetic profile produced by administration of the intravenous pharmaceutical composition using a second dosage regimen of ibuprofen to non-critically ill patients, wherein the at least one condition of the critically ill patient is thereby treated. | 02-03-2011 |
20110028557 | TREATING PATIENTS WITH INTRAVENOUS IBUPROFEN - Methods of treating a patient in need thereof, comprising administering to the critically ill patient an intravenous pharmaceutical composition comprising ibuprofen in an amount effective to treat at least one condition in the patient chosen from pain, inflammation, and fever and to provide a clinically relevant effect on mean arterial pressure of the patients during the dosage interval comprising no increase or no statistically significant increase in mean arterial pressure. | 02-03-2011 |
20110028558 | TREATING CRITICALLY ILL PATIENTS WITH INTRAVENOUS IBUPROFEN - Methods of treating at least one condition chosen from pain, inflammation, and fever in a critically ill patient in need thereof, comprising administering to the critically ill patient an intravenous pharmaceutical composition comprising ibuprofen using a first dosage regimen, wherein the first dosage regimen produces a first pharmacokinetic profile in critically ill patients that is about equivalent to a second pharmacokinetic profile produced by administration of the intravenous pharmaceutical composition using a second dosage regimen of ibuprofen to non-critically ill patients, wherein the at least one condition of the critically ill patient is thereby treated. | 02-03-2011 |
20110039934 | PROCESS FOR THE PREPARATION OF DERIVATIVES OF 1-(2- HALOBIPHENYL-4-YL)-CYCLOPROPANECARBOXYLIC ACID - Compounds according to formula (IA): | 02-17-2011 |
20110054033 | METHODS OF USING ABSCISIC ACID FOR AMELIORATING HYPERTENSION AND VASCULAR INFLAMMATION - Methods and compositions for treating or preventing hypertension or vascular inflammation are described. These methods of the invention involve the administration of abscisic acid (ABA) to subjects in need thereof. | 03-03-2011 |
20110086921 | Novel Polymorphic Forms of (4--2-Methylphenyl)Carbonyl]Amino}-3-Methylphenyl)Acetic Acid - Polymorphic forms 1 and 2 of (4-{[(5-{[(3-chlorophenyl)methyl]oxy}-2-methylphenyl)carbonyl]amino}-3-methylphenyl)acetic acid, pharmaceutical compositions comprising such polymorphs and the use of such polymorphs in medicine. | 04-14-2011 |
20110124730 | ORAL PHARMACEUTICAL SUSPENSION COMPRISING PARACETAMOL AND IBUPROFEN - The present invention relates to an oral pharmaceutical suspension comprising paracetamol and ibuprofen. The invention also relates to a method of treating perioperative or postoperative pain by administering to a subject a therapeutically effective amount of oral pharmaceutical suspension comprising paracetamol and Ibuprofen. | 05-26-2011 |
20110152373 | HAIR GROWTH PROMOTING AGENT CONTAINING 15,15-DIFLUOROPROSTAGLANDIN F2ALPHA DERIVATIVE AS ACTIVE INGREDIENT - The present invention provides a new pharmaceutical application of a 15,15-difluoroprostaglandin F | 06-23-2011 |
20110166233 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS - Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. | 07-07-2011 |
20110166234 | MEDICINAL PRODUCT AND TREATMENT - The use of paracetamol and ibuprofen in the preparation of a medicament for treating osteoarthritis or rheumatoid arthritis, wherein the medicament comprises a combination composition having approximately 125 mg to approximately 150 mg ibuprofen and approximately 475 mg to approximately 500 mg paracetamol. | 07-07-2011 |
20110184066 | Ketoprofen Lysine Salt-Containing Aqueous Patch - A ketoprofen-containing aqueous patch is provided in which not only operational efficiency in producing is improved, but also the aqueous patch has excellent storage stability and transdermal absorption of ketoprofen. The ketoprofen lysine salt-containing aqueous patch includes a backing layer and an adhesive (paste) layer laminated thereon. The aqueous patch includes as a main active ingredient a ketoprofen lysine salt completely dissolved in a paste including not glycerin but a polyethylene glycol having an average molecular weight of 1000 or less. In the ketoprofen lysine salt-containing aqueous patch, the polyethylene glycol having an average molecular weight of 1000 or less is one or more polyethylene glycols selected from the group consisting of Polyethylene glycol 200, Polyethylene glycol 400, Polyethylene glycol 600, and Polyethylene glycol 1000. | 07-28-2011 |
20110201685 | Compositions - An ingestible particulate composition comprises: a) at least one compound selected from the group consisting of 2,4-dichlorobenzyl alcohol, amylmetacresol, cetylpyridinium chloride, hexitidine, hexylresorcinol, flurbiprofen, lidocaine, benzocaine, ibuprofen, paracetamol, pectin, menthol, and benzydamine; and b) one or more bioadhesive materials. Resulting particulate compositions have excellent flow characteristics, dust suppression, organoleptic properties and stability. They are highly suitable for administration direction into a patient's mouth, and ingested to alleviate the symptoms of a sore throat. | 08-18-2011 |
20110230561 | MEDICAL ADHESIVE COMPOSITIONS - A medical adhesive composition comprising, based upon the total weight of the composition, from about 50 wt. % to about 99.9 wt. % of one or more α-cyanoacrylate monomers and from about 0.1 wt. % to about 5 wt. % of one or more non-steroidal anti-inflammatory drugs (NSAIDs). Suitable NSAIDs include ibuprofen and acetaminophen. The resulting compositions provide enhances fibroblast proliferation and reduced cytotoxicity compared to compositions that do not contain NSAID. | 09-22-2011 |
20110245346 | NOVEL POLYMORPHS AND SALTS - Novel polymorphic forms and salts of 1-(3′,4′-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid are useful for the prevention or treatment of Alzheimer's Disease. | 10-06-2011 |
20110263711 | 1-(2-FLUOROBIPHENYL-4-YL)-ALKYL CARBOXYLIC ACID DERIVATIVES FOR THE THERAPY OF TRANSTHYRETIN AMYLOIDOSIS - Derivatives of 1-(2-fluorobiphenyl-4-yl)-alkyl carboxylic acid are capable of stabilizing the tetrameric native state of transthyretin for the prophylaxis and treatment of amyloidosis. | 10-27-2011 |
20110275718 | Pharmaceutical composition of ibuprofen and paracetamol and methods of using the same - A combination pharmaceutical composition for the treatment of pain comprising between about 125 mg and about 150 mg ibuprofen and between about 475 mg and about 500 mg paracetamol, and a method for alleviating pain in a patient comprising administering to the patient a pharmaceutical composition comprising between about 125 mg and about 150 mg ibuprofen and between about 475 mg and about 500 mg paracetamol. | 11-10-2011 |
20110281949 | METHODS AND COMPOSITIONS FOR TREATING NEURONAL DAMAGE AND MODULATING TRANSIENT RECEPTOR POTENTIAL CHANNELS - Use of alkyl phenol and monocyclic monoterpene-derived compounds in the treatment of neuronal damage and in inhibiting activity of TRPC and non-thermo-TRPM channels, and use of bicyclic monoterpene-derived compounds in activating TRPC and non-thermo-TRPM channels. | 11-17-2011 |
20110288175 | 1-PHENYLALKANECARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES - 1-Phenylalkanecarboxylic acid derivatives, the processes for the preparation thereof and the use thereof in the treatment and/or prevention of neurodegenerative diseases such as Alzheimer's disease. | 11-24-2011 |
20110319492 | MANUFACTURE OF TABLETS FROM ENERGY-APPLIED POWDER BLEND - The present invention features a process for making tablets containing one or more pharmaceutically active agent(s) and one or more binder(s), the method including the steps of (i) applying energy to a powder blend comprising the pharmaceutically active agent(s) and the binder(s) for a sufficient period of time to activate the binder(s) within the powder blend and (ii) forming a predetermined amount of the energy-applied powder blend into the tablets. | 12-29-2011 |
20120004308 | METHOD FOR OBTAINING SOLID MICRO- OR NANOPARTICLES - The invention provides a novel method for obtaining solid micro- or nanoparticles with a homogeneous structure. A method is provided for obtaining solid micro- or nanoparticles with a homogeneous structure having a particle size of less than 10 μm where the processed solid compound has the natural, crystalline, amorphous, polymorphic and other features associated with the starting compound. In accordance with the invention a method which also makes it possible to obtain solid micro- or nanoparticles with a substantially spheroidal morphology is provided. | 01-05-2012 |
20120010294 | COMPOSITIONS AND METHODS FOR THE INHIBITION OF MUSCLE CONTRACTION - Compositions and methods for the inhibition of muscle contraction are disclosed. In one aspect, the present application discloses pharmaceutical compositions comprising analgesic agents for the inhibition of muscle contraction. In another aspect, the application discloses methods for the prophylactic intervention against premature pain associated with the filling of the urinary bladder of a subject. In yet another aspect, the application discloses methods for the prophylactic intervention against muscle pain associated with physical activity. | 01-12-2012 |
20120022163 | 1-(2-FLUOROBIPHENYL-4-YL)-CYCLOPROPANECARBOXYLIC ACID DERIVATIVES FOR THE THERAPY OF PRION DISEASES - Derivatives of 1-(2-fluorobiphenyl-4-yl)-cyclopropanecarboxylic acid are useful for the prevention and/or treatment of prion diseases in animals and humans. | 01-26-2012 |
20120095102 | Salts of 3-Pentylphenylacetic Acid and Pharmaceutical Uses Thereof - The present invention relates to salts of 3-pentylphenylacetic acid and their pharmaceutical uses. Particular aspects of the invention relate to the use of those salts in the prevention and/or treatment of various diseases and conditions in subjects, including the prevention and treatment of (i) blood disorders, (ii) renal disorders and renal disorder complications; (iii) inflammatory-related diseases; and/or (iv) oxidative stress related disorders. | 04-19-2012 |
20120136060 | IMMEDIATE RELEASE AND SUSTAINED RELEASE IBUPROFEN DOSING REGIMEN - A method of administering non-steroidal-anti-inflammatory drugs, in particular propionic acid derivatives such as ibuprofen, is provided. The inventive dosage forms provide an initial release of the NSAID and a second sustained release of NSAID, preferably in a single dosing step. | 05-31-2012 |
20120202882 | PERMEATION ENHANCERS FOR TOPICAL FORMULATIONS - A composition to be used as a permeation enhancer is provided. The composition may be added to topical cosmetics or pharmaceutical formulations that are topically applied. The composition comprises about 0.05-5% w/w of one or more phospholipids, 1-20% w/w of one or more oils having essential fatty acids, behenic acid, and oleic acid, 0.1-3% w/w of one or more skin lipids, and 1-10% w/w of a butter having linoleic acid and linolenic acid. One of the oils used in the composition is Pracaxi oil. | 08-09-2012 |
20120208887 | STABLE, LIQUID, READY-TO-USE KETOPROFEN FORMULATIONS - Stable, liquid, ready-to-use ketoprofen formulation for parenteral administration are provided. In some embodiments, the formulation comprises ketoprofen solubilized in a solely aqueous solvent comprising a buffering agent, wherein the composition has a pH of about 5.5 to about 6.5. | 08-16-2012 |
20120220661 | METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF - A method of modulating plasma levels of branched chain amino acids and branched chain alpha-keto acids is disclosed, wherein an ammonia scavenger compound or a salt thereof, for example phenylbutyrate or an even numbered congener thereof or a salt thereof, is administered to an individual in need thereof. In various methods, a decrease in plasma levels of branched chain amino acids and branched chain alpha-keto acids is effected to treat individuals suffering from an inborn error in metabolism of amino acids, such as Maple Syrup Urine Disease, for example. | 08-30-2012 |
20120220662 | PHYTOCEUTICAL COMPOSITIONS FOR PETS - This invention comprises applying phytoceutical compositions to pets, which given their sedentary life and nutrition, are susceptible to a higher prevalence of cancer and degenerative diseases. The compounds contained in said compositions frequently have anti-oxidizing properties acting to inhibit harmful reactions of free radicals; free radicals are often a cause of cancer. Said compositions comprise extracts or concentrates obtained from the enzymatic or alkaline hydrolysis of several plant sources, containing effective concentrations of two or more phenolic compounds, such as ferulic acid, coumaric acid, caffeic acid, protocathecoic acid, and vanillic acid. | 08-30-2012 |
20120232152 | TOPICAL IBUPROFEN FORMULATIONS - The present application relates to a topical formulation comprising ibuprofen, a hydroalcoholic based solvent system, a C | 09-13-2012 |
20120238630 | COMPOSITIONS COMPRISING NONSTEROIDAL ANTI - INFLAMMATORY DRUGS - The present invention describes liquid compositions comprising pharmaceutically active principles, like scarcely water-soluble, nonsteroidal anti-inflammatory drugs, in particular, but not exclusively, flurbiprofen (FP), processes for their manufacture and their therapeutic use. The liquid compositions comprising FP in association with natural polymers, like xyloglucans (XG), and pharmaceutically acceptable excipients like glycerol, are suitable to be used for pharmaceutical uses and are characterized by good tolerability, therapeutic efficacy, stability and palatability. | 09-20-2012 |
20120259018 | COMPOSITION OF DEXIBUPROFEN TRANSDERMAL HYDROGEL - Stable non-alcoholic transdermal hydrogel of dexibuprofen was prepared by using a simple manufacturing process, and the experimental trials showed that the pH modifying agent, antioxidant and water miscible solvent are the essential excipients to obtain stable non-alcoholic transdermal hydrogel of dexibuprofen. The dexibuprofen hydrogel prepared using carbopol as a gelling polymer produced an opaque gel, whereas hydrogel prepared using hyroxypropyl methylcellulose (HPMC) as a gelling polymer produced a transparent gel. There was no significant changes observed with respect to physical description, pH, assay and particularly to the related substance values when the hydrogels were subjected to the stability study at accelerated condition (40° C./75% RH) for 3 months in laminated tubes. | 10-11-2012 |
20120277318 | NON-STEROIDAL ANTI-INFLAMMATORY DRUGS FOR COUGH - The use of a non-steroidal anti-inflammatory drug for the treatment of nonproductive cough caused by viruses or bacteria and a combination of at least one non-steroidal anti-inflammatory drug with at least one antitussive in a formulation to treat coughs. | 11-01-2012 |
20120283329 | S ISOMERS OF ALPHA-METHYL HYDROCINNAMIC ACID FOR THE TREATMENT OF BLOOD DISORDERS - The present intervention generally relates to compositions comprising S-isomer of alpha-methyl-hydrocinnamic acid for the treatment and/or prevention of blood disorders and blood deficiencies, as well as methods for treating blood disorders and/or blood deficiency in a subject by administering a composition comprising S-isomer of alpha-methyl-hydrocinnamic acid to the subject to ameliorate at least one symptom associated with the blood disorder. Another aspect relates to administration of an S-isomer of alpha-methyl-hydrocinnamic acid stimulate multi-lineage hematopoietic cell production in a subject, for example, increasing the numbers of circulating neutrophils, erythrocytes and platelets. Accordingly, one aspect of the present invention relates to administration of S-isomer of alpha-methyl-hydrocinnamic acid, e.g., by oral administration to a subject for the treatment of blood disorders, for example but not limited to, hemaglobinaphthy, thalassemia and aplastic anemia. In some embodiments, the oral pharmaceutical formulation comprising an S-isomer of -α-methyl-hydrocinnamic acid can be used to increase red blood cell proliferation, or increase the proliferation of hemoglobin-expressing cells in a subject in need thereof, e.g., a subject having a blood deficiency such as a subject undergone chemotherapy or radiation exposure or radiation therapy. In some embodiments, a formulation comprising an S-isomer of alpha-methyl-hydrocinnamic acid (ST7S) can be used to simulate myelopiesis or erythropoiesis in a subject in need thereof. | 11-08-2012 |
20120329875 | Ibuprofen for Topical Administration - Set forth herein is a preparation of ibuprofen (2-(4-isobutylphenyl) propionic acid) in the free acid form that is suitable for topical administration. The topical ibuprofen formulation is prepared by dissolving the free acid form of ibuprofen, or preparing a homogeneous suspension of the free acid form of ibuprofen, in the presence of a pharmaceutically acceptable solvent so as to produce a topical drug formulation compatible with the penetration of 2-(4-isobutylphenyl) propionic acid through the skin tissue. Topical formulations of ibuprofen can be based on a pharmaceutically acceptable solvent such as, e.g., a pyrrolidone solvent or dimethylacetamide. | 12-27-2012 |
20130005816 | TRANSDERMAL COMPOSITIONS OF IBUPROFEN AND METHODS OF USE THEREOF - A transdermal composition comprising ibuprofen or salts thereof and a gelling agent which can be used for the treatment of such disorders as pain, inflammation, arthritis, muscle spasm and associated symptoms in humans and animals. | 01-03-2013 |
20130005817 | Ketoprofen-Containing Aqueous Adhesive Skin Patch - Provided is a water-based patch that contains ketoprofen as an active ingredient, provides high transdermal absorbability of the ketoprofen, and has high safety and high storage stability. The water-based patch contains the ketoprofen, an amine, and polyethylene glycol. In the water-based patch, the added amount of the ketoprofen in a paste is 0.1 to 5% by weight, the added amount of the amine in the paste is 0.5 to 10% by weight, and the added amount of the polyethylene glycol in the paste is 5 to 30% by weight. Particularly, in the water-based patch, diisopropanolamine is used as the amine. | 01-03-2013 |
20130035391 | Felbinac-Containing Transdermally Absorbable Preparation - An adhesive patch is a felbinac-containing transdermally absorbable preparation substantially free of a solubilizer for felbinac in a final preparation but still having high releasing of felbinac. The adhesive patch in which lidocaine and felbinac are formulated has the releasing of felbinac without losing the releasing of lidocaine. The felbinac-containing transdermally absorbable adhesive patch contains felbinac as an active component and lidocaine or a pharmaceutically acceptable salt thereof as an absorption promoter. In particular, the content of felbinac is from 0.1% to 10% by weight to the total weight of the drug-containing plaster and the content of lidocaine or the pharmaceutically acceptable salt thereof is from 0.01% to 20% by weight to the total weight of the drug-containing plaster. | 02-07-2013 |
20130035392 | Selective inhibition of the membrane attack complex of complement and C3 convertase by low molecular weight components of the aurin tricarboxylic acid synthetic complex - It pertains to selective inhibition of C3 convertase of the alternative pathway of complement as well as the previously claimed assembly of the membrane attack complex of complement by use of less than 1 kDa molecular weight forms of the aurin tricarboxylic acid synthetic complex (ATAC), and their derivatives. It further pertains to the use of these materials to treat human conditions where there is evidence of self destruction of host tissue by C3 convertase activation of the alternative complement pathway, or the membrane attack complex, or both pathways. These diseases include, but are not limited to, paroxysmal nocturnal hemoglobinemia, rheumatoid arthritis, multiple sclerosis, malaria infection, Alzheimer disease, age related macular degeneration, and atherosclerosis. | 02-07-2013 |
20130041036 | FERULIC ACID AS FEED SUPPLEMENT IN BEEF CATTLE TO PROMOTE ANIMAL GROWTH AND IMPROVE THE MEAT QUALITY OF THE CARCASS AND THE MEAT - The present disclosure comprises a natural method of feed supplement to beef cattle, with a maize extract obtained from the nixtamalization process with a high content of ferulic acid and its salts, for a period of 30 days in the final phase of the feedlot. Use of this dietary supplementation enables an increase in carcass yield and meat quality that is not negatively affected as with a commercial β-agonist. In addition to the above effects, the effective supplementation of ferulic acid to cattle is shown to have antioxidant effects on fresh meat during its shelf life, which can lead to great benefits for the industrial meat market. | 02-14-2013 |
20130053446 | PHARMACEUTICAL PREPARATIONS HAVING INDIVIDUALIZED DOSAGE AND STRUCTURE - A manufacturing device capable of creating individualized dosages of pharmaceutical preparations in which a metering system and a means of performing non-destructive chemical analysis of individual manufactured units are controlled by a microprocessor to precisely control the content and structure of each individual unit. | 02-28-2013 |
20130109756 | Dual Drug Delivery Using Silicone Gels | 05-02-2013 |
20130116327 | Burst Drug Release Compositions - A solid dose composition comprising at least one pharmaceutically active ingredient and at least one controlled release agent and method of manufacturing said composition is disclosed. The burst profile of at least one pharmaceutically active ingredient in the composition is regulated by the apparent viscosity of the controlled release agent and wherein at least one pharmaceutically active ingredient is processed by wet granulation. | 05-09-2013 |
20130172419 | POLYMER COMPOSITES OF SILICONE IONOMERS - A polymer composite composition wherein at least one of the constituents is a silicone ionomer and the other constituent is polymer. | 07-04-2013 |
20130190403 | ADMINISTRATION OF INTRAVENOUS IBUPROFEN TO TRAUMA PATIENTS - A method for treating human patients who require hospitalization for a trauma injury wherein the patients are intravenously administered a first dose of a therapeutically effective dose of ibuprofen intravenously as soon as possible after hospitalization is disclosed. The patients are further treated with intravenous ibuprofen at suitable dosing intervals to the human patient until (a) the patient no longer requires intravenous dosing of ibuprofen. | 07-25-2013 |
20130217774 | NOVEL PROCESS FOR PREPARING DEXIBUPROFEN READY TO COMPRESS GRANULES - Preparing a dexibuprofen pharmaceutical formulation in the form of granules that can be directly compressed into tablets. The process consists of two steps: (i) preparation of base granules, and (ii) blending base granules with a compression aid. The process of preparing base granules involves use of liquid bed granulator with top spray method, or slugging by roll compaction. The granules prepared by using both the methods showed improved compressibility and flowability compared to granules prepared by conventional granulation process using rapid mixer granulator. The ready-to-compress granules prepared by the process show no signs of sticking when compressed on a high-speed commercial scale tablet compression machine. | 08-22-2013 |
20130225685 | COMBINATION COMPOSITION - An intravenous composition for providing relief for pain and/or inflammation, the composition having ibuprofen and paracetamol in combination for delivering to a human at each dose:
| 08-29-2013 |
20130231390 | PHARMACEUTICAL COMPOSITION OF IBUPROFEN FOR INJECTION - Pharmaceutical composition of ibuprofen for injection that comprises an aqueous solution of ibuprofen and trometamol. These compositions display a minimal loss of active principle and acceptable increase of impurities after autoclaving, properties that have been demonstrated in various types of containers, such as containers made of plastics such as polypropylene, PVC and polyethylene, as well as in glass containers. These compositions, after undergoing autoclaving, still comply with all the relevant technical specifications of the European Pharmacopoeia and of the USP. | 09-05-2013 |
20130261188 | Ibuprofen Solid Oral Dosage Composition Comprising a Methacrylic Acid Copolymer - Aspects of the invention include organoleptically acceptable solid oral dosage compositions of ibuprofen. Solid oral dosage compositions according to certain embodiments include ibuprofen and a methacrylic acid copolymer in an amount sufficient to make the composition organoleptically acceptable for administering in an oral cavity of a subject to deliver ibuprofen to the subject. Methods for preparing and using solid oral dosage compositions of the invention are also described. | 10-03-2013 |
20130289121 | PULMONARY DISEASE TREATMENT AND DIAGNOSIS BASED ON ARHGEF1 - Treatment and diagnostic methods are provided for pulmonary disease, including chronic obstructive pulmonary disease, Arhgef1, a leukocyte signaling molecule, functions normally to suppress integrin-mediated MMP production by alveolar macrophages. MMP9 production by fibronectin-stimulated monocytes and macrophages depends on autocrine thromboxane receptor signaling and this signaling pathway is attenuated by Arhgef1. Expression of ARHGEF1 by human peripheral blood monocytes varies between individuals and inversely correlates with fibronectin-mediated MMP9 production. Arhgef1 levels can function as a predictor for a pulmonary disease candidate and a thromboxane receptor antagonist can treat a pulmonary disease condition resulting from low Arhgef1 levels. | 10-31-2013 |
20130345307 | Systems and methods for skin rejuvenation - Systems and methods for skin rejuvenation are disclosed herein. In an embodiment, a skin rejuvenation system includes a unit dose of a booster product that includes active ingredients of ferulic acid and phloretin; a unit dose of at least one exfoliating product that includes active ingredients of ferulic acid and phloretin in combination with fruit acids or alpha hydroxyacids; and a unit dose of a nano-additive product for enhancing penetration of the active ingredients. A method for skin rejuvenation includes applying topically, to a skin surface to be treated, a booster product including active ingredients of ferulic acid and phloretin; applying topically, to the skin surface, at least one exfoliating product including active ingredients of ferulic acid and phloretin in combination with one of fruit acids or alpha hydroxyacids; and applying topically, to the skin surface, a nano-additive product for enhancing penetration of the active ingredients. | 12-26-2013 |
20130345308 | PHARMACEUTICAL AND NUTRACEUTICAL COMPOSITIONS OF ABSCISIC ACID - The invention relates to compositions comprising abscisic acid, and/or salts, derivatives and analogs thereof, and methods of pharmaceutical and/or nutraceutical use. | 12-26-2013 |
20140039057 | Compositions - An ingestible particulate composition including at least one compound selected from the group consisting of 2,4-dichlorobenzyl alcohol, amylmetacresol, cetylpyridinium chloride, hexitidine, hexylresorcinol, flurbiprofen, lidocaine, benzocaine, ibuprofen, paracetamol, pectin, menthol, and benzydamine and one or more bioadhesive materials. Resulting particulate compositions have excellent flow characteristics, dust suppression, organoleptic properties and stability. They are highly suitable for administration direction into a patient's mouth, and ingested to alleviate the symptoms of a sore throat. | 02-06-2014 |
20140073696 | COMBINATION COMPOSITION - A combination pharmaceutical composition for the treatment of pain including about 125 mg to about 150 mg ibuprofen and about 475 mg to about 500 mg paracetamol. | 03-13-2014 |
20140073697 | DELIVERY OF IBUPROFEN AND OTHER COMPOUNDS - The present invention generally relates to the transdermal delivery of various compositions. In some aspects, the transdermal delivery may be facilitated by the use of a hostile biophysical environment. One set of embodiments provides a composition for topical delivery comprising ibuprofen and/or an ibuprofen salt, a nitric oxide donor, and optionally, a hostile biophysical environment. In some cases, the composition may be stabilized using a stabilization polymer such as xanthan gum, KELTROL® BT and/or KELTROL® RD; propylene glycol; and a polysorbate surfactant such as Polysorbate 20, which unexpectedly provides temperature stability to the composition, e.g., at elevated temperatures such as at least 40° C. (at least about 104° F.), as compared to compositions lacking one or more of these. | 03-13-2014 |
20140073698 | PHARMACEUTICAL COMPOSITION COMPRISING KETOPROFEN - The present invention relates to a pharmaceutical formulation of ketoprofen sodium salts in a hydrophilic solvent system suitable as a liquid fill composition. | 03-13-2014 |
20140080912 | Suspension Pharmaceutical Formulations Comprising Low Melting Propionic Acid Derivative Particles - Low melting propionic acid derivative particles that are free flowing and have significantly reduced or eliminated throat burn are disclosed. A method of manufacturing the low melting propionic acid derivative particles; dosage forms containing the low melting propionic acid derivative particles; methods of manufacturing the dosage forms; and methods of treatment using the dosage forms are also disclosed. | 03-20-2014 |
20140088195 | TOPICAL KETOPROFEN COMPOSITION - A topical composition, specifically an oil-in-water emulsion, comprised of ketoprofen and oxybenzone in a physiologically acceptable topical carrier. The composition is applied topically to alleviate pain, especially pain associated with migraine headache. The composition has good photostability as well as freeze/thaw stability. | 03-27-2014 |
20140135399 | NOVEL POLYMORPHS AND SALTS - Novel polymorphic forms and salts of 1-(3′,4′-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid are useful for the prevention or treatment of Alzheimer's Disease. | 05-15-2014 |
20140142185 | 3-Benzyloxyphenyloxoacetic Acid Compounds for Reducing Uric Acid - Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula (I) or its pharmaceutically acceptable salts. The uric acid-lowering effects of the compounds of this invention are used to treat or prevent a variety of conditions including gout, hyperuricemia, elevated levels of uric acid that do not meet the levels customarily justifying a diagnosis of hyperuricemia, renal dysfunction, kidney stones, cardiovascular disease, risk for developing cardiovascular disease, tumor-lysis syndrome, cognitive impairment, early-onset essential hypertension, and | 05-22-2014 |
20140142186 | METHODS OF ADMINISTERING AND EVALUATING NITROGEN SCAVENGING DRUGS FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY - The present disclosure provides methods for treating hepatic encephalopathy (HE) and for optimizing and adjusting nitrogen scavenging drug dosage for subjects with HE. | 05-22-2014 |
20140142187 | Pharmaceutical Suspension Composition - An aqueous oral liquid pharmaceutical composition system with reduced propensity for agglomeration and phase separation which is particularly amendable to the suspension of one or more pharmaceutical actives that are substantially insoluble in water. The oral liquid pharmaceutical composition may further comprise pharmaceutical actives that are soluble in water and dissolve in the aqueous medium. In the composition of the invention both suspended and any dissolved active agents are distributed homogeneously. | 05-22-2014 |
20140155483 | Edible Oral Strip or Wafer Dosage Form Containing Ion Exchange Resin for Taste Masking - An edible oral film strip dosage form containing an unpalatable acidic active pharmaceutical ingredient, particularly ketoprofen, and an ion exchange resin as a primary taste masking agent, along with an optional alkaline agent and further optionally containing one or more secondary taste masking agents is provided. The edible oral film strip dosage matrix is formed from at least one water soluble or miscible polymer(s). The optional secondary taste masking ingredients include one or more of flavoring agent(s), sweetener(s), cooling sensation agent(s), and taste receptor blocker(s). The inventive dosages minimize or completely mask the bitterness, burning sensation and throat irritation associated with many acidic active pharmaceutical ingredients. Methods for preparing the inventive edible oral film strip dosage forms are disclosed, as well as their method of administration. | 06-05-2014 |
20140163108 | ORAL PHARMACEUTICAL DISPERSION COMPOSITIONS - The invention provides an oral pharmaceutical composition, optionally in dose unit form, comprising a lipophilic drug substance in dispersion in a physiologically tolerable aqueous carrier, preferably an aqueous gel, wherein said drug substance contains a functional electrostatic group having a pKa value of from 2 to 10, characterised in that said aqueous carrier has a pH at least 0.3 below or above said pKa value, said pH being below said pKa where said group is acidic and above said pKa where said group is basic. | 06-12-2014 |
20140163109 | TASTE-MASKED IBUPROPEN GRANULES - Taste-masked Ibuprofen granules and a process for preparation thereof, as well as an oral dosage form including such taste-masked Ibuprofen granules and the use of said granules in an oral dosage form. | 06-12-2014 |
20140187636 | CRYSTALLINE FORMS OF BIMATOPROST ACID, METHODS FOR PREPARATION, AND METHODS FOR USE THEREOF - The invention provides new crystalline forms of 7-[3,5-Dihydroxy-2-(3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-hept-5-enoic acid. This compound is commonly referred to as “bimatoprost acid.” The novel crystalline forms are designated forms I, II, and III. The invention crystalline forms are useful for solid ocular implant formulations, utilized in the treatment of various ocular conditions, such as, for example, ocular hypertension. In addition, invention crystalline forms are useful for solid or semisolid dosage formulations used to treat ocular hypertension. | 07-03-2014 |
20140187637 | TROMETHAMINE SALT OF BIMATOPROST ACID IN CRYSTALLINE FORM, METHODS FOR PREPARATION, AND METHODS FOR USE THEREOF - The present invention provides tromethamine salt of 7-[3,5-Dihydroxy-2-(3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-hept-5-enoic acid in crystalline and amorphous form. This compound is may also be referred to as “tromethamine salt of bimatoprost acid.” The invention crystalline form is useful for solid ocular implant or topical formulations, utilized in the treatment of various ocular conditions, such as, for example, ocular hypertension. | 07-03-2014 |
20140200276 | NOVEL FORMULATION OF NAPROXEN - The present invention relates to methods for producing particles of naproxen using dry milling processes as well as compositions comprising naproxen, medicaments produced using naproxen in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of naproxen administered by way of said medicaments. | 07-17-2014 |
20140213652 | METHODS OF SKIN WHITENENING BY USE OF CANOLA EXTRACTS - Compositions and methods for lightening skin are provided. A method for lightening skin may include the step of identifying skin where lightening or whitening is desired and topically applying to the skin a composition including (a) a skin lightening agent comprising a canola extract and (b) a cosmetically acceptable carrier. A method for treating hyperpigmentation may include the step of identifying skin containing areas of hyperpigmentation and topically applying to the skin a composition including (a) a canola extract and (b) a cosmetically acceptable carrier. | 07-31-2014 |
20140213653 | DIRECTLY COMPRESSIBLE PROPRIONIC ACID DERIVATIVE PARTICLES - A compressed tablet containing directly compressible propionic acid derivative particles is disclosed. A method of manufacturing a compressed tablet containing the directly compressible propionic acid derivative particles; and methods of treatment using the compressed tablet are also disclosed. | 07-31-2014 |
20140275264 | SYNERGISTIC COMBINATIONS OF ORGANIC ACID USEFUL FOR CONTROLLING MICROOGANISMS IN INDUSTRIAL PROCESSES - The present invention provides a method of controlling bacterial contamination using synergistic interactions of antimicrobials. The invention utilizes a combination of organic acids where the combined antimicrobial effect is synergistic. | 09-18-2014 |
20140275265 | THERAPEUTIC CREAM FOR APPLICATION TO SKIN - A stable, efficacious therapeutic cream comprising a non-steroidal anti-inflammatory drug (NSAID) is disclosed. | 09-18-2014 |
20140296342 | Pharmaceutical Formulation Comprising NSAID And Cyclodextrin - The present invention provides a liquid composition in comprising an aqueous solution of an NSAID and one or more cyclodextrins. | 10-02-2014 |
20140329904 | INCREASING THE BIOAVAILABILITY OF HYDROXYCINNAMIC ACIDS - The present invention generally relates to the field of nutrition, health and wellness. For example, the present invention relates to hydroxycinnamic acids and their health benefits. The present invention discloses compositions that allow increasing the bioavailability and/or bioefficacy of hydroxycinnamic acids. According to the invention, this can be achieved by co-administering at least one glycoside conjugate of a flavonoid with hydroxycinnamic acids. | 11-06-2014 |
20140336259 | PHENOLIC COMPOUNDS WITH ANTIOXIDANT AND ANTI-CANCER PROPERTIES, ANALOGS AND SYNTHESIS THEREOF - The present document describes a phytochemical isolated from maple syrup and composition comprising the same. More specifically, the document describes an antioxidant phytochemical compound, derivates thereof, and composition comprising the same. The document also describes a process of synthesizing the antioxidant phytochemical compound. | 11-13-2014 |
20140371318 | ORALLY-DISINTEGRATING FORMULATIONS OF FLURBIPROFEN - The present invention relates to an orally-disintegrating pharmaceutical formulation, which is characterized by comprising flurbiprofen and polyvinylcaprolactam-polyvinyl acetate-polyethylene glycol graft copolymer. | 12-18-2014 |
20140378547 | ANTIOXIDANT COMPOSITIONS FOR TREATMENT OF INFLAMMATION OR OXIDATIVE DAMAGE - One embodiment of the invention is directed to a method of preventing, reducing, or eliminating at least one negative effect of oxidative damage, such as an oral disease, caused by a dental device in the mouth of a patient. Another embodiment relates to a method of preventing, reducing, or eliminating at least one negative effect of inflammation. The method may include applying topically to a soft oral tissue in the patient an oral antioxidant composition. The antioxidant composition may include between 0.0001% and 5.0% w/w or at least one antioxidant, wherein the at least one antioxidant includes a natural phytochemcial antioxidant, a flavonoid, an anthocyanidin, a dihydrochalcone, a phenylpropanoid, a chalcone, a curcuminoid, a tannin, a stilbenoid, a coumarin, a carotenoid, or a vitamin, and an orally pharmaceutically acceptable carrier. The pH of the oral antioxidant composition may be at least 5.0. | 12-25-2014 |
20150018420 | METHOD OF CONTROLLING THE RELEASE OF AN ACTIVE INGREDIENT FROM A DOSAGE FORM - A method of controlling or adjusting release of an active ingredient from a dosage form comprising the active ingredient and a polysaccharide derivative has been found. The method comprises the steps of
| 01-15-2015 |
20150018421 | Treatment of Sleep Disturbances - The present invention provides a new composition for treating pain-associated sleep disturbances, especially shortened sleep duration, comprising ibuprofen and diphenhydramine. The composition is further prepared as a bilayer tablet or caplet, or alternatively as a soft gelatin capsule composition, to prevent interaction between the active ingredients. | 01-15-2015 |
20150025150 | METHODS AND COMPOSITIONS FOR TREATING METABOLIC SYNDROME - Provided are methods, compositions, systems, and kits for treating metabolic syndrome or a disorder associated with metabolic syndrome, e.g., obesity, dyslipidemia, and/or a diabetic condition, comprising administering systemically to a subject one or more compounds of the Formula (I) and/or (II): | 01-22-2015 |
20150031768 | C-HALOGEN BOND FORMATION - Methods of halogenating a carbon containing compound having an sp3 C—H bond are provided. Methods of fluorinating a carbon containing compound comprising halogenation with Cl or Br followed by nucleophilic substitution with F are provided. Methods of direct oxidative C—H fluorination of a carbon containing compound having an sp3 C—H bond are provided. The halogenated products of the methods are provided. | 01-29-2015 |
20150051287 | Compositions and Methods for Treating Chronic Inflammation and Inflammatory Diseases - The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions. | 02-19-2015 |
20150057356 | MELT-EXTRUDED COMPOSITION COMPRISING A CELLULOSE ETHER - A melt-extruded polymer composition comprising a) at least one cellulose ether, b) one or more active ingredients and c) one or more optional additives, wherein said at least one cellulose ether has an MS (hydroxyalkyl) of 0.05 to 0.55 and hydroxyl groups of anhydroglucose units are substituted with methyl groups such that [s23/s26−0.2*MS(hydroxyalkyl)] is 0.32 or less, wherein s23 is the molar fraction of anhydroglucose units wherein only the two hydroxyl groups in the 2- and 3-positions of the anhydroglucose unit are substituted with a methyl group and wherein s26 is the molar fraction of anhydroglucose units wherein only the two hydroxyl groups in the 2- and 6-positions of the anhydroglucose unit are substituted with a methyl group. | 02-26-2015 |
20150080470 | TRANSDERMAL DELIVERY OF BENEFICIAL SUBSTANCES EFFECTED BY A HOSTILE BIOPHYSICAL ENVIRONMENT - The present invention generally relates to the transdermal delivery of substances and, in some embodiments, to the transdermal delivery of beneficial substances by a hostile biophysical environment. In one aspect, various methods for the transdermal delivery of beneficial substances are disclosed. By creating a hostile biophysical environment, beneficial substances may be delivered, according to certain embodiments, through the stratum corneum of the skin into the body. Beneficial substances include, but are not limited to, pharmaceutical agents, drugs, vitamins, co-factors, peptides, dietary supplements, and others. The beneficial effects disclosed include, for instance, relief of pain and inflammation, prevention and healing of ulcers of the skin, relief of headache, improved sexual function and enjoyment, growth of hair on the scalp, improving muscle size and/or function, removing body fat and/or cellulite, treating cancer, treating viral infections and others. A hostile biophysical environment may also be used in conjunction with systems and methods for increasing local blood flow, according to one set of embodiments. For example, by using a nitric oxide donor such as L-arginine, local blood flow may be increased, e.g., by transdermally delivering the nitric oxide precursor. The nitric oxide donor may be the sole cause of increased blood flow, or it may be supplemented with an adjunct such as theophylline. | 03-19-2015 |
20150087710 | TREATING CRITICALLY ILL PATIENTS WITH INTRAVENOUS IBUPROFEN - Methods of treating at least one condition chosen from pain, inflammation, and fever in a critically ill patient in need thereof, comprising administering to the critically ill patient an intravenous pharmaceutical composition comprising ibuprofen using a first dosage regimen, wherein the first dosage regimen produces a first pharmacokinetic profile in critically ill patients that is about equivalent to a second pharmacokinetic profile produced by administration of the intravenous pharmaceutical composition using a second dosage regimen of ibuprofen to non-critically ill patients, wherein the at least one condition of the critically ill patient is thereby treated. | 03-26-2015 |
20150094372 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF - The present invention relates to substituted aromatic compounds of Formula I and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds in the prevention and/or treatment of various diseases and conditions in subjects, including the prevention or treatment of (i) blood disorders, (ii) renal disorders, a nephropathies, or renal disorder complications; (iii) inflammatory-related diseases; and/or (iv) oxidative stress related disorders. | 04-02-2015 |
20150105468 | Pharmaceutical Composition of Ibuprofen and Tramadol for Ophthalmic Use - The present invention relates to a pharmaceutical composition of ibuprofen and tramadol for ophthalmic use. Said composition is effective and safe for the treatment of ocular inflammation and/or pain associated to different diseases or pathological states which affect the eye area In particular, the ophthalmic composition of the invention is indicated, for example, for the treatment of pain and/or inflammation after eye surgery. | 04-16-2015 |
20150105469 | METHODS OF TREATING UREA CYCLE DISORDERS - The present disclosure provides novel methods for determining an effective dosage of a PAA prodrug and for treating a UCD that incorporate body surface area and urinary PAGN concentration. The disclosure further provides novel methods for assessing compliance with PAA prodrug administration that incorporate urinary PAGN concentration, and the subject's current dosing regimen, BSA, or age. The disclosure further provides novel methods of treating a UCD in a subject in need thereof that incorporate urinary PAGN concentration, and the subject's current dosing regimen, BSA, and/or age. | 04-16-2015 |
20150297534 | METHODS AND COMPOSITIONS FOR THE MEDIATION OF NSAID-INDUCED REACTIONS - Administration of an NSAID with at least one dual inhibitor of mPGES-1 and NF-κB plus at least one zwitterionic phospholipid rests in a lessening of side effects and the ability to administer smaller doses of an NSAID without loss of effectiveness. | 10-22-2015 |
20150317908 | PATIENT REPORTED OUTCOME INSTRUMENTS FOR ENDOMETRIOSIS - The present invention relates to methods of diagnosing, treating, and monitoring endometriosis utilizing patient reported outcome instruments. | 11-05-2015 |
20150328270 | CANOLA EXTRACTS CONTAINING HIGH LEVELS OF PHENOLIC ACIDS - Disclosed in certain embodiments is a canola extract comprising greater than 30% sinapic acid, pharmaceutical compositions thereof, and methods thereof. | 11-19-2015 |
20150335596 | 1-(2-FLUOROBIPHENYL-4-YL)-CYCLOPROPANECARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DOWN'S SYNDROME - Derivatives of 1-(2-fluorobiphenyl-4-yl)-cyclopropanecarboxylic acid are useful for improving the cognitive capacity of patients with intellectual disabilities, an IQ of less than 85, diagnosed with mental retardation, and, most specifically, those with Down's syndrome. | 11-26-2015 |
20150335747 | INJECTABLE IBUPROFEN FORMULATION - The present invention provides a pharmaceutical composition comprising an aqueous solution of an ibuprofen solubilizing agent and ibuprofen, the ibuprofen solubilizing agent being in an effective amount such that the ibuprofen in the solution remains soluble at concentrations from 100 mg/mL to 5 mg/mL without undergoing a phase transition. The invention further provides a method of treating a condition chosen from pain, inflammation, fever, and/or patent ductus arteriosis, comprising administering to a patient in need thereof an effective amount of an aqueous solution a ibuprofen solubilizing agent and ibuprofen, the ibuprofen solubilizing agent being in an effective amount such that the ibuprofen in the solution remains soluble at concentrations from 100 mg/mL to 5 mg/mL without undergoing a phase transition, as well as a method for manufacturing the composition. | 11-26-2015 |
20150342879 | COMPOSITION OF DEXIBUPROFEN TRANSDERMAL HYDROGEL - Stable non-alcoholic transdermal hydrogel of dexibuprofen was prepared by using a simple manufacturing process, and the experimental trials showed that the pH modifying agent, antioxidant and water miscible solvent are the essential excipients to obtain stable non-alcoholic transdermal hydrogel of dexibuprofen. The dexibuprofen hydrogel prepared using carbopol as a gelling polymer produced an opaque gel, whereas hydrogel prepared using hyroxypropyl methylcellulose (HPMC) as a gelling polymer produced a transparent gel. There was no significant changes observed with respect to physical description, pH, assay and particularly to the related substance values when the hydrogels were subjected to the stability study at accelerated condition (40° C./75% RH) for 3 months in laminated tubes. | 12-03-2015 |
20150359765 | METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF - A method of modulating plasma levels of branched chain amino acids and branched chain alpha-keto acids is disclosed, wherein an ammonia scavenger compound or a salt thereof, for example phenylbutyrate or an even numbered congener thereof or a salt thereof, is administered to an individual in need thereof. In various methods, a decrease in plasma levels of branched chain amino acids and branched chain alpha-keto acids is effected to treat individuals suffering from an inborn error in metabolism of amino acids, such as Maple Syrup Urine Disease, for example. | 12-17-2015 |
20150366829 | DELIVERY OF IBUPROFEN AND OTHER COMPOUNDS - The present invention generally relates to the transdermal delivery of various compositions. In some aspects, the transdermal delivery may be facilitated by the use of a hostile biophysical environment. One set of embodiments provides a composition for topical delivery comprising ibuprofen and/or an ibuprofen salt, a nitric oxide donor, and optionally, a hostile biophysical environment. In some cases, the composition may be stabilized using a stabilization polymer such as xanthan gum, KELTROL® BT and/or KELTROL® RD; propylene glycol; and a polysorbate surfactant such as Polysorbate 20, which unexpectedly provides temperature stability to the composition, e.g., at elevated temperatures such as at least 40° C. (at least about 104° F.), as compared to compositions lacking one or more of these. | 12-24-2015 |
20150376125 | TROMETHAMINE SALT OF BIMATOPROST ACID IN CRYSTALLINE FORM 1, METHODS FOR PREPARATION, AND METHODS FOR USE THEREOF - The present invention provides tromethamine salt of (Z)-7-[3,5-Dihydroxy-2-((E)-3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-hept-5-enoic acid in crystalline Form 1 and amorphous form. This compound is may also be referred to as “tromethamine salt of bimatoprost acid.” The invention crystalline form is useful for solid ocular implant or topical formulations, utilized in the treatment of various ocular conditions, such as, for example, ocular hypertension. | 12-31-2015 |
20160008478 | Pharmaceutical Formulation Comprising NSAID And Cyclodextrin | 01-14-2016 |
20160039736 | Substituted Aromatic Compounds and Related Method for the Treatment of Fibrosis - The present invention relates to compounds of: | 02-11-2016 |
20160045465 | THERAPEUTIC FORMULATIONS FOR THE TREATMENT OF COLD AND FLU-LIKE SYMPTOMS - A pharmaceutical formulation of therapeutically effective amounts of acetaminophen, ibuprofen, and a sympathomimetic drug, such as pseudoephedrine (or its prodrug), or phenylephrine used in the treatment of cold and flu-like symptoms. Such symptoms may include fever, pain, nasal congestion, sinus congestion, runny nose, sore throat, myalgia, ear pressure and fullness, and headache. The formulation further includes various excipients used in the formulation process. | 02-18-2016 |
20160051678 | SUSPENSION PHARMACEUTICAL FORMULATIONS COMPRISING LOW MELTING PROPIONIC ACID DERIVATIVE PARTICLES - Low melting propionic acid derivative particles that are free flowing and have significantly reduced or eliminated throat burn are disclosed. A method of manufacturing the low melting propionic acid derivative particles; dosage forms containing the low melting propionic acid derivative particles; methods of manufacturing the dosage forms; and methods of treatment using the dosage forms are also disclosed. | 02-25-2016 |
20160058721 | FORMULATION FOR TREATING EQUINE INFLAMMATION - It is an object of the present invention to provide an excellent anti-inflammatory drug for external use that is used for treating inflammation observed in animals (myositis, arthritis, neuritis, tendinitis, tenosynovitis, desmitis, bruise, sprain, etc.), and in particular, for the treatment of bowed tendon observed in horses. The solution of the present invention is an external pharmaceutical composition for preventing or treating inflammation observed in animals, which comprises loxoprofen or a salt thereof as an active ingredient. | 03-03-2016 |
20160058722 | METHOD FOR IMPROVING THE OXYGEN-RELEASING ABILITY OF HEMOGLOBIN TO ORGANS AND PERIPHERAL TISSUES IN HUMAN BODIES - A method for improving the oxygen-releasing ability of hemoglobin to organs and peripheral tissues in human bodies is disclosed by administering ferulic acid to a subject in need thereof to improve the oxygen-releasing ability of hemoglobin to the organs and the peripheral tissues in human bodies. Ferulic acid forms a hydrogen bond with αVal1 of hemoglobin, stabilizing the α1/α2 interface of hemoglobin, further stabilizing the oxygenated hemoglobin, hemoglobin variants, recombinant hemoglobin and hemoglobin-based blood substitutes in the low oxygen affinity “T” state and facilitating the oxygen release to the organs and the peripheral tissues. | 03-03-2016 |
20160095830 | CO-ADMINISTRATION OF INTRAVENOUS IBUPROFEN AND ACETAMINOPHEN FOR TREATMENT OF PAIN - An effective dose of intravenous ibuprofen administered co-adminstered with intravenous acetaminophen in surgery patients is a safe and effective way to reduce both pain and the need for opioid analgesics. In preferred embodiments, the administration of intravenous ibuprofen and intravenous acetaminophen starts no later than at approximately the completion of wound closure. | 04-07-2016 |
20160101180 | Compositions and Methods for Treating Severe Pain - The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions. | 04-14-2016 |
20160113894 | TREATING CRITICALLY ILL PATIENTS WITH INTRAVENOUS IBUPROFEN - Methods of treating at least one condition chosen from pain, inflammation, and fever in a critically ill patient in need thereof, comprising administering to the critically ill patient an intravenous pharmaceutical composition comprising ibuprofen using a first dosage regimen, wherein the first dosage regimen produces a first pharmacokinetic profile in critically ill patients that is about equivalent to a second pharmacokinetic profile produced by administration of the intravenous pharmaceutical composition using a second dosage regimen of ibuprofen to non-critically ill patients, wherein the at least one condition of the critically ill patient is thereby treated. | 04-28-2016 |
20160136277 | Ketoprofen-Containing Aqueous Adhesive Skin Patch - Provided is a water-based patch that contains ketoprofen as an active ingredient, provides high transdermal absorbability of the ketoprofen, and has high safety and high storage stability. The water-based patch contains the ketoprofen, an amine, and polyethylene glycol. In the water-based patch, the added amount of the ketoprofen in a paste is 0.1 to 5% by weight, the added amount of the amine in the paste is 0.5 to 10% by weight, and the added amount of the polyethylene glycol in the paste is 5 to 30% by weight. Particularly, in the water-based patch, diisopropanolamine is used as the amine. | 05-19-2016 |
20160151315 | S ISOMERS OF ALPHA-METHYL-HYDROCINNAMIC ACID FOR THE TREATMENT OF BLOOD DISORDERS | 06-02-2016 |
20160158361 | Compositions and Methods for Treating Chronic Inflammation and Inflammatory Diseases - The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions. | 06-09-2016 |
20160175269 | CRYSTALLINE FORMS OF BIMATOPROST ACID, METHODS FOR PREPARATION, AND METHODS FOR USE THEREOF | 06-23-2016 |
20160193165 | NOVEL POLYMORPHS AND SALTS | 07-07-2016 |
20190142944 | INJECTABLE IBUPROFEN FORMULATION | 05-16-2019 |